⌘K
Loading ticker…
As of 2026-08-24, Relmada Therapeutics, Inc. Common Stock (RLMD) has a 3-month relative strength percentile of 12 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 84. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.8%, relative volume 0.76×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RLMD is in a stage 3 topping pattern, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -19.5% / -15.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
RLMD is held by 3 ETFs as of May 2026. Top owner: ONEQ at 0.00% weight, $215K notional. Top 3 carry $294K.
Held by 8 ETFs · $23M across latest filings · largest weight 10.17% (PSIL).
Top 3 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| ONEQ | 0.00% | $215K | new |
| AVUSAvantis U.S. Equity ETF | 0.00% | $52K | new |
| AVSC | 0.00% | $27K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RLMD Jan avg: -12.03% median: -15.79% win: 25% σ: 22.34% n: 4 2022-04-12 → 2026-07-31 | RLMD Feb avg: 11.87% median: 8.56% win: 50% σ: 37.17% n: 4 2022-04-12 → 2026-07-31 | RLMD Mar avg: -1.21% median: -10.12% win: 50% σ: 39.77% n: 4 2022-04-12 → 2026-07-31 | RLMD Apr avg: 3.22% median: 8.05% win: 60% σ: 15.77% n: 5 2022-04-12 → 2026-07-31 | RLMD May avg: 19.69% median: -4.12% win: 40% σ: 64.75% n: 5 2022-04-12 → 2026-07-31 | RLMD Jun avg: -7.26% median: -4.02% win: 40% σ: 9.10% n: 5 2022-04-12 → 2026-07-31 | RLMD Jul avg: 8.74% median: 6.50% win: 80% σ: 21.85% n: 5 2022-04-12 → 2026-07-31 | RLMD Aug avg: 24.82% median: 21.42% win: 75% σ: 42.86% n: 4 2022-04-12 → 2026-07-31 (current) | RLMD Sep avg: 27.74% median: 21.38% win: 75% σ: 38.04% n: 4 2022-04-12 → 2026-07-31 | RLMD Oct avg: -15.81% median: 3.54% win: 50% σ: 44.93% n: 4 2022-04-12 → 2026-07-31 | RLMD Nov avg: 10.43% median: -15.30% win: 25% σ: 59.71% n: 4 2022-04-12 → 2026-07-31 | RLMD Dec avg: -8.25% median: -8.92% win: 50% σ: 62.78% n: 4 2022-04-12 → 2026-07-31 |